Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia

Pharmacology and Therapeutics

Volumn 101, Issue 1, 2004, Pages 17-38

  Le Goff, Wilfried ^a,b   Guerin, Maryse ^a   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Dyslipidemia; HDL; LDL; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROBUCOL; PROTEIN INHIBITOR; SEX HORMONE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTERYL ESTER TRANSFER PROTEIN DEFICIENCY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; GENE EXPRESSION; GENE MUTATION; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; IMMUNIZATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPID TRANSPORT; METABOLIC SYNDROME X; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN STRUCTURE; RABBIT; REVIEW; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

EID: 0347948456     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2003.10.001     Document Type: Review

References (245)

1. Abbey M., Calvert G.D. Effects of blocking plasma lipid transfer protein activity in the rabbit. Biochim Biophys Acta. 1003:1989;20-29.
2. Adlouni A., El Messal M., Saile R., Parra H., Fruchart J., Ghalim N. Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. Atherosclerosis. 152:2000;433-440.
3. Agellon L.B., Quinet E.M., Gillette T.G., Drayna D.T., Brown M.L., Tall A.R. Organization of the human cholesteryl ester transfer protein gene. Biochemistry. 29:1990;1372-1376.
4. Agellon L.B., Walsh A., Hayek T., Moulin P., Jiang X.C., Shelanski S.A., Breslow J.L., Tall A.R. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem. 266:1991;10796-10801.
5. Ahnadi C.E., Berthezene F., Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis. 99:1993;219-228.
6. Albers J.J., Tollefson J.H., Wolfbauer G., Albright R.E. Jr. Cholesteryl ester transfer protein in human brain. Int J Clin Lab Res. 21:1992;264-266.
7. Arad Y., Ramakrishnan R., Ginsberg H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 31:1990;567-582.
8. Arai T., Yamashita S., Hirano K., Sakai N., Kotani K., Fujioka S., Nozaki S., Keno Y., Yamane M., Shinohara E. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb. 14:1994;1129-1136.
9. Arai T., Yamashita S., Sakai N., Hirano K., Okada S., Ishigami M., Maruyama T., Yamane M., Kobayashi H., Nozaki S., Funahashi T., Kameda-Takemura K., Nakajima N., Matsuzawa Y. A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res. 37:1996;2145-2154.
10. Arai T., Tsukada T., Murase T., Matsumoto K. Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. Clin Chim Acta. 301:2000;103-117.
11. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., Schaefer E.J. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis. 164:2002;361-369.
12. Au-Young J., Fielding C.J. Synthesis and secretion of wild-type and mutant human plasma cholesteryl ester transfer protein in baculovirus- transfected insect cells: the carboxyl-terminal region is required for both lipoprotein binding and catalysis of transfer. Proc Natl Acad Sci USA. 89:1992;4094-4098.
13. Bagdade J.D., Ritter M.C., Subbaiah P.V. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest. 87:1991;1259-1265.
14. Bagdade J.D., Ritter M.C., Subbaiah P.V. Accelerated cholesteryl ester transfer in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 21:1991;161-167.
15. Bagdade J.D., Lane J.T., Subbaiah P.V., Otto M.E., Ritter M.C. Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis. 104:1993;69-77.
16. Bagdade J.D., Kelley D.E., Henry R.R., Eckel R.H., Ritter M.C. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes. 46:1997;414-420.
17. Barter P.J., Jones M.E. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J Lipid Res. 21:1980;238-249.
18. Barter P.J., Lally J.I. In vitro exchanges of esterified cholesterol between serum lipoprotein fractions: studies of humans and rabbits. Metabolism. 28:1979;230-236.
19. Barter P.J., Ha Y.C., Calvert G.D. Studies of esterified cholesterol in sub-fractions of plasma high density lipoproteins. Atherosclerosis. 38:1981;165-175.
20. Barter P.J., Chang L.B., Newnham H.H., Rye K.A., Rajaram O.V. The interaction of cholesteryl ester transfer protein and unesterified fatty acids promotes a reduction in the particle size of high-density lipoproteins. Biochim Biophys Acta. 1045:1990;81-89.
21. Barter P.J., Brewer H.B. Jr., Chapman M.J., Hennekens C.H., Rader D.J., Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 23:2003;160-167.
22. Beamer L.J., Carroll S.F., Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 276:1997;1861-1864.
23. Beentjes J.A., van Tol A., Sluiter W.J., Dullaart R.P. Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis. 153:2000;491-498.
24. Beentjes J.A., van Tol A., Sluiter W.J., Dullaart R.P. Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy. Scand J Clin Lab Invest. 60:2000;189-198.
25. Beentjes J.A., van Tol A., Sluiter W.J., Dullaart R.P. Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults. J Lipid Res. 41:2000;925-932.
26. Bertiere M.C., Fumeron F., Rigaud D., Malon D., Apfelbaum M., Girard-Globa A. Low high density lipoprotein-2 concentrations in obese male subjects. Atherosclerosis. 73:1988;57-61.
27. Bhatnagar D., Durrington P.N., Mackness M.I., Arrol S., Winocour P.H., Prais H. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis. 92:1992;49-57.
28. Bhatnagar D., Durrington P.N., Kumar S., Mackness M.I., Dean J., Boulton A.J. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes. 44:1995;460-465.
29. Bhatnagar D., Durrington P.N., Kumar S., Mackness M.I., Boulton A.J. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabetes Med. 13:1996;139-144.
30. Bierman E.L. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb. 12:1992;647-656.
31. Bonn V., Cheung R.C., Chen B., Taghibiglou C., Van Iderstine S.C., Adeli K. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 163:2002;59-68.
32. Brown M.L., Inazu A., Hesler C.B., Agellon L.B., Mann C., Whitlock M.E., Marcel Y.L., Milne R.W., Koizumi J., Mabuchi H., Takeda R., Tall A.R. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:1989;448-451.
33. Bruce C., Beamer L.J., Tall A.R. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol. 8:1998;426-434.
34. Bulow B., Hagmar L., Mikoczy Z., Nordstrom C.H., Erfurth E.M. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 46:1997;75-81.
35. Cao G., Beyer T.P., Yang X.P., Schmidt R.J., Zhang Y., Bensch W.R., Kauffman R.F., Gao H., Ryan T.P., Liang Y., Eacho P.I., Jiang X.C. Phospholipid transfer protein is regulated by liver×receptors in vivo. J Biol Chem. 277:2002;39561-39565.
36. Carrilho A.J., Cunha-Neto M.B., Nunes V.S., Lottenberg A.M., Medina W.L., Nakandakare E.R., Musolino N.R., Bronstein M.D., Quintao E.C. Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone-deficient adult humans. Lipids. 36:2001;549-554.
37. Carroll P.V., Christ E.R., Bengtsson B.A., Carlsson L., Christiansen J.S., Clemmons D., Hintz R., Ho K., Laron Z., Sizonenko P., Sonksen P.H., Tanaka T., Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 83:1998;382-395.
38. Castelli W.P. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 70:1992;3-9.
39. Castro G.R., Fielding C.J. Effects of postprandial lipemia on plasma cholesterol metabolism. J Clin Invest. 75:1985;874-882.
40. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis. 171:2003;1-13.
41. Cheung M.C., Wolf A.C., Lum K.D., Tollefson J.H., Albers J.J. Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J Lipid Res. 27:1986;1135-1144.
42. Chiba H., Eto M., Fujisawa S., Akizawa K., Intoh S., Miyata O., Noda K., Matsuno K., Kobayashi K. Increased plasma apolipoprotein E-rich high-density lipoprotein and its effect on serum high-density lipoprotein cholesterol determination in patients with familial hyperalphalipoproteinemia due to cholesteryl ester transfer activity deficiency. Biochem Med Metab Biol. 49:1993;79-89.
43. Chiba H., Akita H., Tsuchihashi K., Hui S.P., Takahashi Y., Fuda H., Suzuki H., Shibuya H., Tsuji M., Kobayashi K. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res. 38:1997;1204-1216.
44. Chiesa G., Michelagnoli S., Cassinotti M., Gianfranceschi G., Werba J.P., Pazzucconi F., Sirtori C.R., Franceschini G. Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism. 42:1993;229-235.
45. Chouinard R.A. Jr., Luo Y., Osborne T.F., Walsh A., Tall A.R. Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vivo but is not required for sterol up-regulation of gene expression. J Biol Chem. 273:1998;22409-22414.
46. Clay M.A., Newnham H.H., Forte T.M., Barter P.I. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim Biophys Acta. 1124:1992;52-58.
47. Colhoun H.M., Scheek L.M., Rubens M.B., Van Gent T., Underwood S.R., Fuller J.H., Van Tol A. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes. 50:2001;652-659.
48. Contacos C., Barter P.J., Vrga L., Sullivan D.R. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis. 141:1998;87-98.
49. Corbex M., Poirier O., Fumeron F., Betoulle D., Evans A., Ruidavets J.B., Arveiler D., Luc G., Tiret L., Cambien F. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. (in process citation) Genet Epidemiol. 19:2000;64-80.
50. Dachet C., Poirier O., Cambien F., Chapman J., Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol. 20:2000;507-515.
51. Davidson M.H., Maki K., Umporowicz D., Wheeler A., Rittershaus C., Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 169:2003;113-120.
52. De Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., van Tol A., Kastelein J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2002;2159-2165.
53. Deighan C.J., Caslake M.J., McConnell M., Boulton-Jones J.M., Packard C.J. The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis. 157:2001;211-220.
54. Dejager S., Bruckert E., Chapman M.J. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 34:1993;295-308.
55. De Man F.H., Cabezas M.C., Van Barlingen H.H., Erkelens D.W., de Bruin T.W. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest. 26:1996;89-108.
56. Dinchuk J., Hart J., Gonzalez G., Karmann G., Schmidt D., Wirak D.O. Remodelling of lipoproteins in transgenic mice expressing human cholesteryl ester transfer protein. Biochim Biophys Acta. 1255:1995;301-310.
57. Drayna D., Lawn R. Multiple RFLPs at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res. 15:1987;4698.
58. Drayna D., Jarnagin A.S., McLean J., Henzel W., Kohr W., Fielding C., Lawn R. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 327:1987;632-634.
59. Dullaart R.P., Hoogenberg K., Groener J.E., Dikkeschei L.D., Erkelens D.W., Doorenbos H. The activity of cholesteryl ester transfer protein is decreased in hypothyroidism: a possible contribution to alterations in high-density lipoproteins. Eur J Clin Invest. 20:1990;581-587.
60. Dullaart R.P., Groener J.E., Dikkeschei B.D., Erkelens D.W., Doorenbos H. Elevated cholesteryl ester transfer protein activity in IDDM men who smoke. Possible factor for unfavorable lipoprotein profile. Diabetes Care. 14:1991;338-341.
61. Dullaart R.P., Sluiter W.J., Dikkeschei L.D., Hoogenberg K., Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 24:1994;188-194.
62. Dullaart R.P., Riemens S.C., Scheek L.M., Van Tol A. Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. Eur J Clin Invest. 29:1999;663-671.
63. Duntas L.H. Thyroid disease and lipids. Thyroid. 12:2002;287-293.
64. Durrington P.N., Mackness M.I., Bhatnagar D., Julier K., Prais H., Arrol S., Morgan J., Wood G.N. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis. 138:1998;217-225.
65. Eisenberg S. Preferential enrichment of large-sized very low density lipoprotein populations with transferred cholesteryl esters. J Lipid Res. 26:1985;487-494.
66. Elchebly M., Porokhov B., Pulcini T., Berthezene F., Ponsin G. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis. 123:1996;93-101.
67. Ellsworth J.L., Kashyap M.L., Jackson R.L., Harmony J.A. Human plasma lipid transfer protein catalyzes the speciation of high density lipoproteins. Biochim Biophys Acta. 918:1987;260-266.
68. Evans G.F., Bensch W.R., Apelgren L.D., Bailey D., Kauffman R.F., Bumol T.F., Zuckerman S.H. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution. J Lipid Res. 35:1994;1634-1645.
69. Faucher C., Doucet C., Baumelou A., Chapman J., Jacobs C., Thillet J. Elevated lipoprotein (a) levels in primary nephrotic syndrome. Am J Kidney Dis. 22:1993;808-813.
70. Fielding C.J., Reaven G.M., Fielding P.E. Human noninsulin-dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by selective immunoadsorption of apolipoprotein E. Proc Natl Acad Sci USA. 79:1982;6365-6369.
71. Fielding C.J., Reaven G.M., Liu G., Fielding P.E. Increased free cholesterol in plasma low and very low density lipoproteins in non-insulin-dependent diabetes mellitus: its role in the inhibition of cholesteryl ester transfer. Proc Natl Acad Sci USA. 81:1984;2512-2516.
72. Franceschini G., Sirtori M., Vaccarino V., Gianfranceschi G., Rezzonico L., Chiesa G., Sirtori C.R. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 9:1989;462-469.
73. Franceschini G., Lovati M.R., Manzoni C., Michelagnoli S., Pazzucconi F., Gianfranceschi G., Vecchio G., Sirtori C.R. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis. 114:1995;61-71.
74. Francone O.L., Gurakar A., Fielding C. Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem. 264:1989;7066-7072.
75. Francone O.L., Royer L., Haghpassand M. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res. 37:1996;1268-1277.
76. Fumeron F., Betoulle D., Luc G., Behague I., Ricard S., Poirier O., Jemaa R., Evans A., Arveiler D., Marques-Vidal P., Bard J.M., Fruchart J.C., Ducimetierre P., Apfelbaum M., Cambien F. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest. 96:1995;1664-1671.
77. Funke H., Wiebusch H., Fuer L., Muntoni S., Schulte H., Assmann G. Identification of mutations in the cholesterol ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. Circulation. 90:1994;I-241. (Abstract).
78. Gambert P., Bouzerand-Gambert C., Athias A., Farnier M., Lallemant C. Human low density lipoprotein subfractions separated by gradient gel electrophoresis: composition, distribution, and alterations induced by cholesteryl ester transfer protein. J Lipid Res. 31:1990;1199-1210.
79. Gaudet F., Ginsburg G.S. Transcriptional regulation of the cholesteryl ester transfer protein gene by the orphan nuclear hormone receptor apolipoprotein AI regulatory protein-1. J Biol Chem. 270:1995;29916-29922.
80. Gauthier B., Robb M., Gaudet F., Ginsburg G.S., McPherson R. Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: functional role of the transcription factors SREBP-1a, -2, and YY1. J Lipid Res. 40:1999;1284-1293.
81. Gautier T., Masson D., De Barros J.P., Athias A., Gambert P., Aunis D., Metz-Boutigue M.H., Lagrost L. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem. 275:2000;37504-37509.
82. Gaynor B.J., Sand T., Clark R.W., Aiello R.J., Bamberger M.J., Moberly J.B. Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis. 110:1994;101-109.
83. Goldberg D.I., Beltz W.F., Pittman R.C. Evaluation of pathways for the cellular uptake of high density lipoprotein cholesterol esters in rabbits. J Clin Invest. 87:1991;331-346.
84. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease: II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 52:1973;1544-1568.
85. Gotoda T., Kinoshita M., Shimano H., Harada K., Shimada M., Ohsuga J., Teramoto T., Yazaki Y., Yamada N. Cholesteryl ester transfer protein deficiency caused by a nonsense mutation detected in the patient's macrophage mRNA. Biochem Biophys Res Commun. 194:1993;519-524.
86. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver×receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 277:2002;34182-34190.
87. Groener J.E., Van Rozen A.J., Erkelens D.W. Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man. Atherosclerosis. 50:1984;261-271.
88. Guérin M., Dolphin P.J., Chapman M.J. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb. 14:1994;679-685.
89. Guérin M., Dolphin P.J., Chapman M.J. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb. 14:1994;199-206.
90. Guérin M., Dolphin P.J., Talussot C., Gardette J., Berthezene F., Chapman M.J. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;1359-1368.
91. Guérin M., Bruckert E., Dolphin P.J., Chapman M.J. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia. Eur J Clin Invest. 26:1996;485-494.
92. Guérin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 16:1996;763-772.
93. Guérin M., Lassel T.S., Le Goff W., Farnier M., Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 20:2000;189-197.
94. Guérin M., Le Goff W., Lassel T.S., van Tol A., Steiner G., Chapman M.J. Proatherogenic role of elevated CET from HDL to VLDL1 and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 21:2001;282-288.
95. Guérin M., Egger P., Soudant C., Le Goff W., van Tol A., Dupuis R., Chapman M.J. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res. 43(10):2002;1652-1660.
96. Guérin M., Egger P., Soudant C., Le Goff W., van Tol A., Dupuis R., Chapman M.J. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 163:2002;287-296.
97. Guérin M., Le Goff W., Frisdal E., Schneider S., Milosavljevic D., Bruckert E., Chapman M.J. Action of ciprofibrate in type IIB hyperlipidemia: modulation of the atherogenic lipoprotein phenotype and stimulation of HDL-mediated cellular cholesterol efflux. J Clin Endocrinol Metab. 88:2003;3738-3746.
98. Ha Y.C., Barter P.J. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B. 71:1985;265-269.
99. Hayashibe H., Asayama K., Nakane T., Uchida N., Kawada Y., Nakazawa S. Increased plasma cholesteryl ester transfer activity in obese children. Atherosclerosis. 129:1997;53-58.
100. Hayashibe H., Asayama K., Nakane T., Kobayashi K., Amemiya S., Nakazawa S. Decreased activity of plasma cholesteryl ester transfer protein in children and adolescents with insulin-dependent diabetes mellitus. Acta Paediatr. 88:1999;1067-1070.
101. Hayek T., Chajek-Shaul T., Walsh A., Agellon L.B., Moulin P., Tall A.R., Breslow J.L. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J Clin Invest. 90:1992;505-510.
102. Hayek T., Azrolan N., Verdery R.B., Walsh A., Chajek-Shaul T., Agellon L.B., Tall A.R., Breslow J.L. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J Clin Invest. 92:1993;1143-1152.
103. Hesler C.B., Swenson T.L., Tall A.R. Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem. 262:1987;2275-2823.
104. Hesler C.B., Tall A.R., Swenson T.L., Weech P.K., Marcel Y.L., Milne R.W. Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J Biol Chem. 263:1988;5020-5023.
105. Hirano K., Yamashita S., Kuga Y., Sakai N., Nozaki S., Kihara S., Arai T., Yanagi K., Takami S., Menju M., Ishigami M., Yoshida Y., Kameda-Takemura K., Hayashi K., Matsuzawa Y. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol. 15:1995;1849-1856.
106. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sakai N., Kameda-Takemura K., Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 17:1997;1053-1059.
107. Hirano R., Igarashi O., Kondo K., Itakura H., Matsumoto A. Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells. Lipids. 36:2001;401-406.
108. Homma Y., Ozawa H., Kobayashi T., Yamaguchi H., Sakane H., Mikami Y., Nakamura H. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis. 106:1994;191-201.
109. Hopkins G.J., Chang L.B., Barter P.J. Role of lipid transfers in the formation of a subpopulation of small high density lipoproteins. J Lipid Res. 26:1985;218-229.
110. Huang Z., Inazu A., Nohara A., Higashikata T., Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci. 103(6):2002;587-594.
111. Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 67:1983;968-977.
112. Iglesias A., Montelongo A., Herrera E., Lasuncion M.A. Changes in cholesteryl ester transfer protein activity during normal gestation and postpartum. Clin Biochem. 27:1994;63-68.
113. Ihm J., Quinn D.M., Busch S.J., Chataing B., Harmony J.A. Kinetics of plasma protein-catalyzed exchange of phosphatidylcholine and cholesteryl ester between plasma lipoproteins. J Lipid Res. 23:1982;1328-1341.
114. Ikewaki K., Rader D.J., Sakamoto T., Nishiwaki M., Wakimoto N., Schaefer J.R., Ishikawa T., Fairwell T., Zech L.A., Nakamura H., Nagano M., Brewer H.B. Jr. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest. 92:1993;1650-1658.
115. Ikewaki K., Nishiwaki M., Sakamoto T., Ishikawa T., Fairwell T., Zech L.A., Nagano M., Nakamura H., Brewer H.B. Jr., Rader D.J. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest. 96:1995;1573-1581.
116. Inazu A., Brown M.L., Hesler C.B., Agellon L.B., Koizumi J., Takata K., Maruhama Y., Mabuchi H., Tall A.R. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 323:1990;1234-1238.
117. Inazu A., Jiang X.C., Haraki T., Yagi K., Kamon N., Koizumi J., Mabuchi H., Takeda R., Takata K., Moriyama Y., Doi M., Tall A. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 94:1994;1872-1882.
118. Inazu A., Koizumi J., Kajinami K., Kiyohar T., Chichibu K., Mabuchi H. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis. 145:1999;405-413.
119. Ishigami M., Yamashita S., Sakai N., Arai T., Hirano K., Hiraoka H., Kameda-Takemura K., Matsuzawa Y. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency cannot protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem (Tokyo). 116:1994;257-262.
120. Ishigami M., Yamashita S., Sakai N., Hirano K.I., Arai T., Maruyama T., Takami S., Koyama M., Kameda-Takemura K., Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 27:1997;285-292.
121. Ishikawa Y., Ito K., Akasaka Y., Ishii T., Masuda T., Zhang L., Akishima Y., Kiguchi H., Nakajima K., Hata Y. The distribution and production of cholesteryl ester transfer protein in the human aortic wall. Atherosclerosis. 156:2001;29-37.
122. Izem L., Morton R.E. Cholesteryl ester transfer protein biosynthesis and cellular cholesterol homeostasis are tightly interconnected. J Biol Chem. 14:2001;14.
123. Jap T.S., Wu Y.C., Tso Y.C., Chiu C.Y. A novel mutation in the intron 1 splice donor site of the cholesterol ester transfer protein (CETP) gene as a cause of hyperalphalipoproteinemia. Metabolism. 51:2002;394-397.
124. Jensen J., Nilas L., Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 12:1990;321-331.
125. Jeoung N.H., Jang W.G., Nam J.I., Pak Y.K., Park Y.B. Identification of retinoic acid receptor element in human cholesteryl ester transfer protein gene. Biochem Biophys Res Commun. 258:1999;411-415.
126. Jiang X.C., Moulin P., Quinet E., Goldberg I.J., Yacoub L.K., Agellon L.B., Compton D., Schnitzer-Polokoff R., Tall A.R. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem. 266:1991;4631-4639.
127. Jones R.J., Owens D., Brennan C., Collins P.B., Johnson A.H., Tomkin G.H. Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II. Atherosclerosis. 119:1996;151-157.
128. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M., Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA. 99:2002;7604-7609.
129. Kahri J., Groop P.H., Viberti G., Elliott T., Taskinen M.R. Regulation of apolipoprotein A-I-containing lipoproteins in IDDM. Diabetes. 42:1993;1281-1288.
130. Kakko S., Tamminen M., Kesaniemi Y.A., Savolainen M.J. R451Q mutation in the cholesteryl ester transfer protein (CETP) gene is associated with high plasma CETP activity. Atherosclerosis. 136:1998;233-240.
131. Kakko S., Tamminen M., Paivansalo M., Kauma H., Rantala A.O., Lilja M., Reunanen A., Kesaniemi Y.A., Savolainen M.J. Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur J Clin Invest. 31:2001;593-602.
132. Kawano K., Qin S.C., Lin M., Tall A.R., Jiang X.C. Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. J Biol Chem. 275:2000;29477-29481.
133. Klerkx A.H., Tanck M.W., Kastelein J.J., Molhuizen H.O., Jukema J.W., Zwinderman A.H., Kuivenhoven J.A. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet. 12(2):2003;111-123.
134. Kobayashi J., Okamoto H., Otabe M., Bujo H., Saito Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis. 162:2002;131-135.
135. Koizumi J., Mabuchi H., Yoshimura A., Michishita I., Takeda M., Itoh H., Sakai Y., Sakai T., Ueda K., Takeda R. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 58:1985;175-186.
136. Korhonen T., Hannuksela M.L., Seppanen S., Kervinen K., Kesaniemi Y.A., Savolainen M.J. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Eur J Clin Pharmacol. 54:1999;903-910.
137. Kothari H.V., Poirier K.J., Lee W.H., Satoh Y. Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis. 128:1997;59-66.
138. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.V., Lie K.I., Kastelein J.J. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. (see comments) N Engl J Med. 338:1998;86-93.
139. Kunitake S.T., Mendel C.M., Hennessy L.K. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res. 33:1992;1807-1816.
140. Lagrost L. Effect of the human cholesteryl ester transfer protein on the particle size redistribution of specific subpopulations of high density lipoproteins-3. Biochim Biophys Acta. 1126:1992;143-150.
141. Lagrost L. The role of cholesteryl ester transfer protein and phospholipid transfer protein in the remodeling of plasma high-density lipoproteins. Trends Cardiovasc Med. 7:1997;218-224.
142. Lagrost L., Gandjini H., Athias A., Guyard-Dangremont V., Lallemant C., Gambert P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 13:1993;815-825.
143. Lagrost L., Athias A., Gambert P., Lallemant C. Comparative study of phospholipid transfer activities mediated by cholesteryl ester transfer protein and phospholipid transfer protein. J Lipid Res. 35:1994;825-835.
144. Lagrost L., Gambert P., Lallemant C. Combined effects of lipid transfers and lipolysis on gradient gel patterns of human plasma LDL. Arterioscler Thromb. 14:1994;1327-1336.
145. Lagrost L., Athias A., Herbeth B., Guyard-Dangremont V., Artur Y., Paille F., Gambert P., Lallemant C. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem. 271:1996;19058-19065.
146. Lagrost L., Athias A., Lemort N., Richard J.L., Desrumaux C., Chatenet-Duchene L., Courtois M., Farnier M., Jacotot B., Braschi S., Gambert P. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis. 143:1999;415-425.
147. Le N.A., Innis-Whitehouse W., Li X., Bakker-Arkema R., Black D., Brown W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 49:2000;167-177.
148. Le Goff W., Guérin M., Nicaud V., Dachet C., Luc G., Arveiler D., Ruidavets J.B., Evans A., Kee F., Morrison C., Chapman M.J., Thillet J. A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma HDL-C levels: interaction with the TaqIB and -629C/A polymorphisms. Atherosclerosis. 162(2):2002;269-279.
149. Le Goff W., Guérin M., Chapman M.J., Thillet J. A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression. J Lipid Res. 44:2003;902-910.
150. Le Goff W., Guérin M., Petit L., Chapman M.J., Thillet J. Regulation of human CETP gene expression: role of SP1 and SP3 transcription factors at promoter sites -690, -629, and -37. J Lipid Res. 44:2003;1322-1331.
151. Lewis-Barned N.J., Sutherland W.H., Walker R.J., Walker H.L., De Jong S.A., Edwards E.A., Markham V.H. Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women. J Clin Endocrinol Metab. 84:1999;3534-3538.
152. Lie J., de Crom R., Jauhiainen M., van Gent T., van Haperen R., Scheek L., Jansen H., Ehnholm C., van Tol A. Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of prebeta-high-density lipoproteins. Biochem J. 360:2001;379-385.
153. Lottenberg S.A., Lottenberg A.M., Nunes V.S., McPherson R., Quintao E.C. Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates to lighter density lipoproteins in the fasting state and after a test meal are similar in type II diabetics and normal controls. Atherosclerosis. 127:1996;81-90.
154. Lund E.G., Menke J.G., Sparrow C.P. Liver×receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 23:2003;1169-1177.
155. Luo Y., Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 105:2000;513-520.
156. Luo Y., Liang Cp C., Tall A.R. The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by LXR. J Biol Chem. 276:2001;24767-24773.
157. Lusis A.J., Zollman S., Sparkes R.S., Klisak I., Mohandas T., Drayna D., Lawn R.M. Assignment of the human gene for cholesteryl ester transfer protein to chromosome 16q12-16q21. Genomics. 1:1987;232-235.
158. Maclean P.S., Tanner C.J., Houmard J.A., Barakat H.A. Plasma cholesteryl ester transfer protein activity is not linked to insulin sensitivity. Metabolism. 50:2001;783-788.
159. Mann C.J., Yen F.T., Grant A.M., Bihain B.E. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 88:1991;2059-2066.
160. Marcel Y.L., McPherson R., Hogue M., Czarnecka H., Zawadzki Z., Weech P.K., Whitlock M.E., Tall A.R., Milne R.W. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest. 85:1990;10-17.
161. Marotti K.R., Castle C.K., Murray R.W., Rehberg E.F., Polites H.G., Melchior G.W. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arterioscler Thromb. 12:1992;736-744.
162. Marzetta C.A., Meyers T.J., Albers J.J. Lipid transfer protein-mediated distribution of HDL-derived cholesteryl esters among plasma apo B-containing lipoprotein subpopulations. Arterioscler Thromb. 13:1993;834-841.
163. Matsuzawa Y., Yamashita S., Funahashi T., Yamamoto A., Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol. 62:1988;66B-72B.
164. McPherson R., Hogue M., Milne R.W., Tall A.R., Marcel Y.L. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb. 11:1991;476-481.
165. McPherson R., Mann C.J., Tall A.R., Hogue M., Martin L., Milne R.W., Marcel Y.L. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb. 11:1991;797-804.
166. Melchior G.W., Castle C.K., Murray R.W., Blake W.L., Dinh D.M., Marotti K.R. Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels. J Biol Chem. 269:1994;8044-8051.
167. Miida T., Yamaguchi T., Tsuda T., Okada M. High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. Atherosclerosis. 138:1998;129-134.
168. Milosavljevic D., Griglio S., Le Naour G., Chapman M.J. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis. 155:2001;251-260.
169. Moriyama Y., Okamura T., Inazu A., Doi M., Iso H., Mouri Y., Ishikawa Y., Suzuki H., Iida M., Koizumi J., Mabuchi H., Komachi Y. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med. 27:1998;659-667.
170. Morton R.E. Binding of plasma-derived lipid transfer protein to lipoprotein substrates. The role of binding in the lipid transfer process. J Biol Chem. 260:1985;12593-12599.
171. Morton R.E., Zilversmit D.B. A plasma inhibitor of triglyceride and cholesteryl ester transfer activities. J Biol Chem. 256:1981;11992-11995.
172. Morton R.E., Zilversmit D.B. Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem. 258:1983;11751-11757.
173. Moulin P., Appel G.B., Ginsberg H.N., Tall A.R. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res. 33:1992;1817-1822.
174. Moulin P., Cheung M.C., Bruce C., Zhong S., Cocke T., Richardson H., Tall A.R. Gender effects on the distribution of the cholesteryl ester transfer protein in apolipoprotein A-I-defined lipoprotein subpopulations. J Lipid Res. 35:1994;793-802.
175. Nagano M., Yamashita S., Hirano K., Kujiraoka T., Ito M., Sagehashi Y., Hattori H., Nakajima N., Maruyama T., Sakai N., Egashira T., Matsuzawa Y. Point mutation (-69 g → a) in the promoter region of cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. Arterioscler Thromb Vasc Biol. 21:2001;985-990.
176. Nagano M., Yamashita S., Hirano K., Ito M., Maruyama T., Ishihara M., Sagehashi Y., Oka T., Kujiraoka T., Hattori H., Nakajima N., Egashira T., Kondo M., Sakai N., Matsuzawa Y. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by invader assay. J Lipid Res. 43:2002;1011-1018.
177. Newnham H.H., Barter P.J. Synergistic effects of lipid transfers and hepatic lipase in the formation of very small high-density lipoproteins during incubation of human plasma. Biochim Biophys Acta. 1044:1990;57-64.
178. Newnham H.H., Barter P.J. Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase. Biochim Biophys Acta. 1125:1992;297-304.
179. Nikkila E.A. High density lipoproteins in diabetes. Diabetes. 30:1981;82-87. (suppl).
180. Nishida H.I., Arai H., Nishida T. Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins. J Biol Chem. 268:1993;16352-16360.
181. Ohta T., Nakamura R., Takata K., Saito Y., Yamashita S., Horiuchi S., Matsuda I. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J Lipid Res. 36:1995;696-704.
182. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
183. Okamoto H., Iwamoto Y., Maki M., Sotani T., Yonemori F., Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol. 466(1-2):2003;14-54.
184. Ordonez J.D., Hiatt R.A., Killebrew E.J., Fireman B.H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 44:1993;638-642.
185. Ou J., Saku K., Jimi S., Ohta T., Zhang B., Pownall H.J., Shimada Y., Tsujita Y., Arakawa K. Mechanism of action of probucol on cholesteryl ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene. Biochim Biophys Acta. 1393:1998;153-160.
186. Owens D., Cox M., Caird J., Gilligan S., Collins P., Johnson A., Tomkin G.H. Altered regulation of cholesterol metabolism in type I diabetic women during the menstrual cycle. Diabetes Med. 10:1993;647-653.
187. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 17:1997;3542-3556.
188. Patsch J.R. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis. 110:1994;S23-S26. (suppl).
189. Quinet E., Tall A., Ramakrishnan R., Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest. 87:1991;1559-1566.
190. Quinet E.M., Huerta P., Nancoo D., Tall A.R., Marcel Y.L., McPherson R. Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. J Lipid Res. 34:1993;845-852.
191. Ravnik S.E., Zarutskie P.W., Muller C.H. Purification and characterization of a human follicular fluid lipid transfer protein that stimulates human sperm capacitation. Biol Reprod. 47:1992;1126-1133.
192. Riemens S., van Tol A., Sluiter W., Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis. 140:1998;71-79.
193. Ritsch A., Drexel H., Amann F.W., Pfeifhofer C., Patsch J.R. Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol. 17:1997;3433-3441.
194. Ritsch A., Doppler W., Pfeifhofer C., Sandhofer A., Bodner J., Patsch J.R. Cholesteryl ester transfer protein gene expression is not specifically regulated by CCAAT/enhancer-binding protein in HepG2-cells. Atherosclerosis. 146:1999;11-18.
195. Ritter M.C., Bagdade J.D. Contribution of glycaemic control, endogenous lipoproteins and cholesteryl ester transfer protein to accelerated cholesteryl ester transfer in IDDM. Eur J Clin Invest. 24:1994;607-614.
196. Ritter M.C., Kannan C.R., Bagdade J.D. The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer. J Clin Endocrinol Metab. 81:1996;797-800.
197. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., Callow A.D., Marsh H.C., Ryan U.S. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;2106-2112.
198. Rye K.A., Hime N.J., Barter P.J. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem. 272:1997;3953-3960.
199. Sacks F.M., McPherson R., Walsh B.W. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 154:1994;1106-1110.
200. Sakai N., Matsuzawa Y., Hirano K., Yamashita S., Nozaki S., Ueyama Y., Kubo M., Tarui S. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb. 11:1991;71-79.
201. Sakai N., Yamashita S., Hirano K., Ishigami M., Arai T., Kobayashi K., Funahashi T., Matsuzawa Y. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. Eur J Clin Invest. 25:1995;332-339.
202. Sakai N., Santamarina-Fojo S., Yamashita S., Matsuzawa Y., Brewer H.B. Jr. Exon 10 skipping caused by intron 10 splice donor site mutation in cholesteryl ester transfer protein gene results in abnormal downstream splice site selection. J Lipid Res. 37:1996;2065-2073.
203. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., Takeda K., Nakagawa M. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoproteins in patients with mixed hyperlipoproteinemia. Am J Cardiol. 89:2002;386-389.
204. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., Staels B., Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348.
205. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 14:2000;2831-2838.
206. Serdyuk A.P., Morton R.E. Lipid transfer inhibitor protein defines the participation of lipoproteins in lipid transfer reactions: CETP has no preference for cholesteryl esters in HDL versus LDL. Arterioscler Thromb Vasc Biol. 19:1999;718-726.
207. Shedlarz, D. L. (2003). http://www.pfizer.com/download/investors/ presentations/11_12_03_CIBC_1.pdf .
208. Silliman K., Tall A.R., Kretchmer N., Forte T.M. Unusual high-density lipoprotein subclass distribution during late pregnancy. Metabolism. 42:1993;1592-1599.
209. Speijer H., Groener J.E., van Ramshorst E., van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis. 90:1991;159-168.
210. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
211. Stampfer M.J., Colditz G.A., Willett W.C. Menopause and heart disease. A review. Ann NY Acad Sci. 592:1990;193-203.
212. Subbaiah P.V., Rodby R.A. Abnormal acyltransferase activities and accelerated cholesteryl ester transfer in patients with nephrotic syndrome. Metabolism. 43:1994;1126-1133.
213. Sugano M., Makino N. Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J Biol Chem. 271:1996;19080-19083.
214. Sugano M., Makino N., Sawada S., Otsuka S., Watanabe M., Okamoto H., Kamada M., Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 273:1998;5033-5036.
215. Sutherland W.H., Walker R.J., Lewis-Barned N.J., Pratt H., Tillman H.C. Plasma cholesteryl ester transfer in patients with non-insulin dependent diabetes mellitus. Clin Chim Acta. 231:1994;29-38.
216. Swenson T.L., Brocia R.W., Tall A.R. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J Biol Chem. 263:1988;5150-5157.
217. Swenson T.L., Hesler C.B., Brown M.L., Quinet E., Trotta P.P., Haslanger M.F., Gaeta F.C., Marcel Y.L., Milne R.W., Tall A.R. Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. J Biol Chem. 264:1989;14318-14326.
218. Takahashi K., Jiang X.C., Sakai N., Yamashita S., Hirano K., Bujo H., Yamazaki H., Kusunoki J., Miura T., Kussie P., Matsuzawa Y., Saito Y., Tall A. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest. 92:1993;2060-2064.
219. Tall A.R. Plasma lipid transfer proteins. Annu Rev Biochem. 64:1995;235-257.
220. Tall A.R. An overview of reverse cholesterol transport. Eur Heart J. 19(Suppl A):1998;A31-A35.
221. Tall A.R., Abreu E., Shuman J. Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. J Biol Chem. 258:1983;2174-2180.
222. Tall A., Sammett D., Granot E. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia. J Clin Invest. 77:1986;1163-1172.
223. Talmud P.J., Edwards K.L., Turner C.M., Newman B., Palmen J.M., Humphries S.E., Austin M.A. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation. 101:2000;2461-2466.
224. Tamminen M., Kakko S., Kesaniemi Y.A., Savolainen M.J. A polymorphic site in the 3′ untranslated region of the cholesteryl ester transfer protein (CETP) gene is associated with low CETP activity. Atherosclerosis. 124:1996;237-247.
225. Tan K.C., Shiu S.W., Janus E.D., Lam K.S. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis. 129:1997;59-65.
226. Tan K.C., Shiu S.W., Kung A.W. Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab. 83:1998;2921-2924.
227. Tan K.C., Shiu S.W., Kung A.W. Plasma cholesteryl ester transfer protein activity in hyper- and hypothyroidism. J Clin Endocrinol Metab. 83:1998;140-143.
228. Tato F., Vega G.L., Tall A.R., Grundy S.M. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 15:1995;112-120.
229. Teh E.M., Dolphin P.J., Breckenridge W.C., Tan M.H. Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. J Lipid Res. 39:1998;442-456.
230. Tollefson J.H., Faust R., Albers J.J., Chait A. Secretion of a lipid transfer protein by human monocyte-derived macrophages. J Biol Chem. 260:1985;5887-5890.
231. Vadlamudi S., MacLean P., Israel R.G., Marks R.H., Hickey M., Otvos J., Barakat H. Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins. Metabolism. 47:1998;1222-1226.
232. Wang S., Deng L., Milne R.W., Tall A.R. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. J Biol Chem. 267:1992;17487-17490.
233. Warwick G.L., Packard C.J. Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant. 8:1993;385-396.
234. Wheeler D.C., Bernard D.B. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis. 23:1994;331-346.
235. Whitlock M.E., Swenson T.L., Ramakrishnan R., Leonard M.T., Marcel Y.L., Milne R.W., Tall A.R. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest. 84:1989;129-137.
236. Williams S., Hayes L., Elsenboss L., Williams A., Andre C., Abramson R., Thompson J.F., Milos P.M. Sequencing of the cholesteryl ester transfer protein 5′ regulatory region using artificial transposons. Gene. 197:1997;101-107.
237. Yamada T., Kawata M., Arai H., Fukasawa M., Inoue K., Sato T. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. Acta Neuropathol (Berl). 90:1995;633-636.
238. Yamashita S., Matsuzawa Y., Okazaki M., Kako H., Yasugi T., Akioka H., Hirano K., Tarui S. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis. 70:1988;7-12.
239. Yamashita S., Sprecher D.L., Sakai N., Matsuzawa Y., Tarui S., Hui D.Y. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest. 86:1990;688-695.
240. Yamashita S., Hui D.Y., Wetterau J.R., Sprecher D.L., Harmony J.A., Sakai N., Matsuzawa Y., Tarui S. Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. Metabolism. 40:1991;756-763.
241. Yamashita S., Maruyama T., Hirano K., Sakai N., Nakajima N., Matsuzawa Y. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis. 152:2000;271-285.
242. Yen F.T., Deckelbaum R.J., Mann C.J., Marcel Y.L., Milne R.W., Tall A.R. Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. J Clin Invest. 83:1989;2018-2024.
243. Zhang Z., Yamashita S., Hirano K., Nakagawa-Toyama Y., Matsuyama A., Nishida M., Sakai N., Fukasawa M., Arai H., Miyagawa J., Matsuzawa Y. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis. 159:2001;67-75.
244. Zhong S., Sharp D.S., Grove J.S., Bruce C., Yano K., Curb J.D., Tall A.R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 97:1996;2917-2923.
245. Zuliani G., Hobbs H.H. Eco NI polymorphism in the human cholesteryl ester transfer protein (CETP) gene. Nucleic Acids Res. 18:1990;2834.